Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Alzprotect (France)
Homepage:
alzprotect.com
Alternate names:
Alzprotect,
Alzprotect SAS
ROR:
05kk7gg34
OpenAlex ID:
I4405265732
Works
19
Awards
2
AZP2006, a new promising treatment for Alzheimer’s and related diseases
2021
·
N. Callizot
, C. Estrella
, et al.
·
Scientific Reports
·
37
PDF
Chloroquine and Chloroquinoline Derivatives as Models for the Design of Modulators of Amyloid Peptide Precursor Metabolism
2015
·
Patricia Melnyk
, Valérie Vingtdeux
, et al.
·
ACS Chemical Neuroscience
·
33
First-In-Human Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of AZP2006, A Synthetic Compound for the Treatment of Alzheimer’s Disease and Related Diseases
2024
·
Philippe Verwaerde
, Cecilia Estrella
, et al.
·
Journal of Alzheimer s Disease
·
10
AZP2006 in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open‐Label Extension on Safety, Biomarkers, and Disease Progression
2025
·
Jean‐Christophe Corvol
, Mickael Alexandre Obadia
, et al.
·
Movement Disorders
·
5
PDF
AZP2006 (Ezeprogind®): a Promising New Drug Candidate in the Battle Against Neurodegenerative Diseases
2025
·
Philippe Verwaerde
, Olivier Defert
·
ChemMedChem
·
4
AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex
2026
·
Noelle Callizot
, Georgia Culley
, et al.
·
PLoS ONE
·
1
PDF
Pharmacomodulations around an anti-Alzheimer drug-candidate
2021
·
Sylvain Marc
, Christophe Mésangeau
, et al.
·
European Journal of Medicinal Chemistry Reports
·
1
PDF
P1–007: Assessment of cognitive deficits and blood biomarkers of neurodegenerative disease progression in an aged nonhuman primate
2013
·
Solène Languille
, Sandra Bonhomme
, et al.
·
Alzheimer s & Dementia
·
1
Toll-like receptor 9 contributes in microglial activation and lysosomal dysfunction to promote Alzheimer’s disease
2026
·
Moïse de Lavaissière de Lavergne
, Lucie Mazzola
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
AZP2006 in Progressive Supranuclear Palsy: A Multi-Centre, Randomized, Phase 2a Trial Assessing Safety and Biomarker Outcomes
2024
·
Jean-Christophe Corvol
, Mickael Alexandre Obadia
, et al.
·
SSRN Electronic Journal
AZP2006 in Progressive Supranuclear Palsy: A Multi-Centre, Randomized, Phase 2a Trial Assessing Safety and Biomarker Outcomes
2024
·
Jean-Christophe Corvol
, Mickael Alexandre Obadia
, et al.
·
SSRN Electronic Journal
Effect of AZP2006, a new treatment for Alzheimer’s Disease and Progressive Supranuclear Palsy, in the Restoration of Lysosomal Homeostasis via the Progranulin‐Prosaposin Axis
2023
·
Noelle Callizot
, Cecilia Estrella
, et al.
·
Alzheimer s & Dementia
PDF
AZP2006, a New Promising Treatment for Progressive Supranuclear Palsy patients. Phase 2a Study Assessing Tolerability, Safety and Pharmacokinetics. Effect on Biomarkers and Clinical Readouts
2023
·
Philippe Verwaerde
, Cecilia Estrella
, et al.
·
Alzheimer s & Dementia
PDF
New gamma carboline compounds usable in the treatment of neurodegenerative diseases
2017
·
Melnyk, Patricia
, Carato, Pascal
, et al.
·
HAL
P4‐350: Biomarkers of Short Term Disease Progression in Mild Cognitive Impairment Patients with ad Pathology
2016
·
Moira Marizzoni
, Samantha Galluzzi
, et al.
·
Alzheimer s & Dementia
PDF
Beta and gamma carbolines compounds usable in the treatment of neurodegenerative diseases.
2014
·
Melnyk, Patricia
, Carato, Pascal
, et al.
·
HAL
New N-substituted carbolines derivatives for the treatment of neurodegenerative diseases.
2013
·
Melnyk, Patricia
, Carato, Pascal
, et al.
·
HAL
New Beta carbolines derivatives for the treatment of neurodegenerative diseases.
2013
·
Melnyk, Patricia
, Carato, Pascal
, et al.
·
HAL
New Gamma carbolines derivatives for the treatment of neurodegenerative diseases.
2013
·
Melnyk, Patricia
, Carato, Pascal
, et al.
·
HAL
Show more works
View as search
Works count:
19
Citation count:
550
Year
Topic
Type
